Lazard Asset Management
NERV icon

Lazard Asset Management’s Minerva Neurosciences NERV Stock Holding History

Lazard Asset Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,084
Closed -$19K – 2505
2022
Q3 		$19K Buy
+2,084
New +$12.3K ﹤0.01% 2095

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lazard Asset Management's NERV Position: Q4 2022 in Review

Lazard Asset Management sold out of Minerva Neurosciences (NERV) in Q4 2022, closing a stake of 2,084 shares — an estimated $19K sold.

Lazard Asset Management first reported a position in NERV in Q3 2022 and held it in 1 quarter. The position peaked at $19K in Q3 2022. 19 funds tracked by Wall St. Rank hold NERV as of Q4 2022.

  • Lazard Asset Management reported no remaining Minerva Neurosciences position as of Q4 2022 after selling out during the quarter.
  • Lazard Asset Management sold 2,084 Minerva Neurosciences shares in Q4 2022, an estimated $19K.
  • Lazard Asset Management first reported a position in Minerva Neurosciences in Q3 2022 and held it in 1 quarter.
  • Lazard Asset Management's Minerva Neurosciences position peaked at $19K in Q3 2022.
  • 19 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2022.

Based on Lazard Asset Management's 13F filing for Q4 2022, filed 15 Feb 2023.